Last reviewed · How we verify

NCT01908075: REACH

REACH Fostair vs Seretide - Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management

Completed Last updated 24 July 2013
What this trial tests

trial testing FP/SAL in Asthma in 194,723 participants. Completed in 1 March 2013.

Timeline
1 January 2011
Primary endpoint
1 March 2013
1 March 2013

Quick facts

Lead sponsorResearch in Real-Life Ltd
StatusCompleted
Study typeOBSERVATIONAL
Enrollment194,723
Start date1 January 2011
Primary completion1 March 2013
Estimated completion1 March 2013

Drugs / interventions tested

Conditions studied

Sponsor

Research in Real-Life Ltd — full company profile →

Who can join

Adults 18 to 80, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

To evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of FP/SAL

Trials testing the same drug.

Other recruiting trials for Asthma

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01908075.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing